Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease by Lucza, Tivadar et al.
Research Article
Screening Mild and Major Neurocognitive Disorders in
Parkinson’s Disease
Tivadar Lucza,1 Kázmér Karádi,1 János Kállai,1 Rita Weintraut,1 József Janszky,2,3
Attila Makkos,2 Sámuel Komoly,2 and Norbert Kovács2,3
1 Institute of Behavioral Sciences, Faculty of Medicine, University of Pe´cs, Szigeti Utca 12, Pe´cs 7624, Hungary
2Department of Neurology, Faculty of Medicine, University of Pe´cs, Re´t Utca 2, Pe´cs 7623, Hungary
3MTA-PTE Clinical Neuroimaging MR Research Group, Pe´cs, Re´t Utca 23, Pe´cs 7623, Hungary
Correspondence should be addressed to Norbert Kova´cs; kovacsnorbert06@gmail.com
Received 23 February 2015; Revised 28 April 2015; Accepted 11 May 2015
Academic Editor: Evzen Ruzicka
Copyright © 2015 Tivadar Lucza et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. Among the nonmotor features of Parkinson’s disease (PD), cognitive impairment is one of the most troublesome
problems. New diagnostic criteria for mild and major neurocognitive disorder (NCD) in PD were established by Diagnostic and
Statistical Manual ofMental Disorders 5th edition (DSM-5).The aim of our study was to establish the diagnostic accuracy of widely
used screening tests for NCD in PD.Methods. Within the scope of our study we evaluated the sensitivity and specificity of different
neuropsychological tests (Addenbrooke’s Cognitive Examination (ACE),Mattis Dementia Rating Scale (MDRS),MiniMental State
Examination (MMSE), and Montreal Cognitive Assessment (MoCA)) in 370 PD patients without depression. Results. MoCA and
ACE feature the finest diagnostic accuracy for detectingmild cognitive disorder in PD (DSM-5) at the cut-off scores of 23.5 and 83.5
points, respectively.The diagnostic accuracy of these tests was 0.859 (95% CI: 0.818–0.894, MoCA) and 0.820 (95% CI: 0.774–0.859,
ACE). In the detection of major NCD (DSM-5), MoCA andMDRS tests exhibited the best diagnostic accuracy at the cut-off scores
of 20.5 and 132.5 points, respectively.The diagnostic accuracy of these tests was 0.863 (95% CI: 0.823–0.897, MoCA) and 0.830 (95%
CI: 0.785–0.869, MDRS). Conclusion. Our study demonstrated that the MoCAmay be the most suitable test for detecting mild and
major NCD in PD.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by both motor and nonmotor symptoms
including depression, fatigue, and autonomic problems.
Among nonmotor features, cognitive impairment has one of
the most serious consequences by diminishing the quality
of life and requiring an increase in caregiver’s burden [1–
4]. Based on the findings of long-term follow-up studies,
neurocognitive impairment unavoidably evolves by disease
progression [5, 6]. According to some recent studies, the
prevalence of dementia in PD is approximately 20–40% [7];
furthermore, patients with PD have a sixfold risk to develop
dementia compared to healthy controls [8].
Although detection of neurocognitive impairment is of
the utmost clinical importance, this task is difficult to accu-
rately perform [9]. One of the problems is the heterogeneity
of definitions. Previously, the Movement Disorders Society
(MDS) Task Force created definitions for dementia in PD
(PDD) [9] and mild cognitive impairment in PD (PD-
MCI) [10–12]. Moreover, the PD-MCI diagnosis can also be
based on two assessment levels: abbreviated (Level I) and
comprehensive (Level II) [10–12].
Although the MDS criteria for PDD and PD-MCI have
been highly recognized by movement disorder specialists,
there are some countries where the diagnosis of cognitive
impairment has to be determined by psychiatrists. Until the
publication of the most recent version of Diagnostic and
Statistical Manual of Mental Disorders (5th edition, DSM-5)
in 2013 [13], the diagnosis of PD-MCI was impossible from
psychiatric point of view due to the lack of appropriate defini-
tions. According to DSM-5, minor andmajor neurocognitive
disorders (NCD) in PD may be diagnosed which can be
considered as the equivalent versions for PD-MCI and PDD,
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respectively. Comparing to the previous version (DSM 4th
edition text revision, DSM-IVTR), the establishment of mild
andmajor NCD in PD is an important enhancement, because
previously only the dementia in PD was defined. Therefore,
a less severe level of cognitive impairment could not be
coded and diagnosed by DSM-4TR. The newly recognized
term of mild NCD due to PD may facilitate research and
change clinical practice (e.g., patient selection for deep brain
stimulation surgery).
According to DSM-5 mild and major NCD may be
diagnosed if evidence of significant or modest cognitive
decline from a previous level of performance in one or
more cognitive domains can be established, respectively.This
evidence must be supported by both the concern of the
individual, a knowledgeable informant, or the examining
clinician noting a significant decline in cognitive function,
and a substantial impairment in cognitive performance,
preferably documented by standardized neuropsychologi-
cal testing or, in its absence, another quantified clinical
assessment. In the case of major NCD the cognitive deficits
interfere with independence in everyday activities, whereas
in minor NCD the cognitive deficits do not interfere with
capacity for independence in everyday activities, but greater
effort, compensatory strategies, or accommodation may be
required.
The problem with the establishment of diagnosis is
the lack of appropriate clinical screening testing. An ideal
screening test should be brief, fast, and appropriately sensitive
and specific for detecting subjects possessing characteristics
of cognitive impairment [14].
Detection ofminor andmajorNCD inParkinson’s disease
is an important task, because cognitive decline is a frequent
and important exclusion criteria for deep brain stimulator
implantation [15]. Therefore, the necessity of proper screen-
ing for cognitive impairment in PD is highly encouraged in
clinical practice.
Currently, MiniMental State Examination (MMSE) is the
most commonly used tool for screening cognitive abilities
in Hungary [16, 17]. Although it can evaluate orientation,
memory, visual abilities, attention and calculation, language,
writing, reading, and constructive capabilities, it is not
sensitive enough for identifying frontal and executive deficits,
and visuospatial dysfunctions. Moreover, it has a limited
poor sensitivity for detecting dementia in early stages [18, 19]
and it is also unable to differentiate between major types
of dementia if applied alone [20]. Although MMSE has
been translated and validated into many languages and used
in many countries [21], it remains unsuitable for judging
eligibility for deep brain stimulation of the subthalamic nuclei
(STN DBS) [14, 22]. Best cut-off value for MMSE is 26 points
with the sensitivity of 79.9% and specificity of 74.0% for
detecting PDD [14], but for PD-MCI it remains unsuitable for
screening [23].
Therefore, other dementia screening tests are needed in
clinical practice. Although Addenbrooke’s Cognitive Exam-
ination (ACE) is able to detect early stages of dementia
and differentiate some subtypes, its applicability is limited
in PD by the lack of widely applicable normative data [14].
ACE also evaluates the major domains of PDD such as
orientation, attention and mental flexibility, episodic and
semantic memory, verbal fluency, phonemic and semantic
category, aphasia tasks, and visuospatial and constructional
ability. However, ACE was initially developed by Mathu-
ranath et al. for differentiating between Alzheimer’s disease
(AD) and frontotemporal dementia (FTD) [24]. The maxi-
mum score on ACE is 100 points. ACE was translated into
many languages including Hungarian, but it has mainly been
tested in AD and not in PD. ACEwas validated in PD in some
countries [25]. It has limited (<80%) specificity for detecting
PDD (the best cut-off score identifying PDD was 80 points,
sensitivity = 74.0%, specificity = 78.1%, positive predictive
value = 67.42%, negative predictive value = 83.42%) [14].
Therefore, both the original and the revised version of ACE
(ACE-R) must be used cautiously as a screening tool for PD-
MCI, with results largely influenced by its fluency subdomain
score and patient education levels [26, 27].
Mattis Dementia Rating Scale (MDRS) is also a widely
used screening instrument for evaluating dementia. It can
measure the domains of attention, initiation and persever-
ation, construction, conceptualization, and memory. MDRS
seems to be sensitive for mediotemporal and frontal pathol-
ogy [28, 29]. Respectfully, the authors generally agree it is
one of the most frequently used screening tools for judging
cognitive impairment in European DBS centers [30, 31].
Moreover, it is a recommended scale for PD-MCI and PD-
D according to MDS criteria at Level I [11, 32]. Its maximum
obtainable score is 144 points, whereas the cut-off scores for
dementia in French and Spanish PD population was 130 and
123 points, respectively [30, 33]. For the Hungarian version,
MDRS had a good sensitivity and specificity for detecting
PDD (sensitivity = 89.8%, specificity = 98.3%) using the
cut-off score of 125 point [14]. Because the administration
of MDRS requires a lengthy period (approximately 30–45
minutes) in clinical setting, MDRS is not an appropriate tool
to identify dementia in PD in all occasions.
Montreal Cognitive Assessment (MoCA) was developed
as a brief, 10-minute bedside assessment tool for detec-
tion of mild cognitive impairment and dementia in AD.
It measures 7 domains of cognitive functioning, including
visuospatial/executive functions, naming, memory, atten-
tion, language, abstraction, and orientation [34]. Comparing
toMMSE,MoCA is amore sensitive tool for testing executive,
visuospatial functions and attention, which areas are most
often impaired in PD. MoCA also has high interrater, test-
retest reliability [35], and good discriminant validity for
assessing dementia in PD [36, 37]. Further studies demon-
strate that MoCA is able to assess broader cognitive domains,
and it has higher sensitivity for detecting mild cognitive
impairment and dementia in PD [38, 39]. Larner demon-
strated better sensitivity and specificity of ACE-R andMoCA
over MMSE by comparison [40]. MoCA has been translated
and validated into several languages [41–44] and has several
alternative forms to overcome the potential practice effects
[45, 46].
With reference to the authors’ awareness none of the
above mentioned screening tools were validated against the
diagnostic criteria of DSM-5. Therefore, the aim of our
study was to establish the diagnostic accuracy of Montreal
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Cognitive Assessment (version 7.2) as compared to other
widely used screening tests for detecting mild and major
neurocognitive disorder in a large sample of Hungarian PD
patients.
2. Methods
2.1. Participants. Four hundred and seventy-two consecutive
PD patients treated at Department of Neurology, University
of Pe´cs, were recruited for this study. Each patient fulfilled
the clinical diagnostic criteria for idiopathic PD [47]. All of
the subjects provided a written informed consent according
to the approval of the Regional Ethical Board of University of
Pe´cs.
History of cerebrovascular disease, alcoholism, or other
conditions known to impair mental status besides PD served
as exclusion criteria for participation. Each patient had a
routine brain MRI (or brain CT if MRI was contraindicated).
Patients with focal abnormalities on neuroimaging studies,
abnormalities in thyroid hormone levels, or noncompensated
systemic diseases (i.e., diabetes, hypertension, heart failure)
were also excluded.
2.2. Patient Evaluation. Patients were evaluated using
Hungarian versions of Lille Apathy Scale (LARS) [48],
Montgomery-Asberg Depression Rating Scale (MADRS)
[49], MMSE [14, 16], ACE [24, 50], MDRS [28], and MoCA
[44]. Severity of the Parkinsonian symptoms was assessed
by the Hoehn & Yahr (HYS) [51] and the Hungarian
validated version of Movement Disorders Society Unified
Parkinson’s Disease Rating Scales (MDS-UPDRS) [52, 53].
The administering of the applied tests was alternated one
from the other to diminish the potential of sequential effect.
Patients suffering from depression were excluded from
clinical investigation (score > 18 on MADRS and/or fulfilling
the criteria of DSM-5 for depression) to minimize the impact
of affective syndromes on cognitive performance. Subse-
quently, the nondepressed PD patients were divided into
three groups based on the fulfillment of the clinical diagnostic
criteria for minor and major NCD in PD: patients with
major neurocognitive disorder (major NCD group), patients
with minor neurocognitive disorder (minor NCD group),
and patients without either minor or major neurocognitive
disorder (normal PD group) [13]. To increase reliability, a
single experienced investigator (NK) categorized each patient
into normal, minor NCD, and major NCD groups.
2.3. Data Analysis. Statistical analyses were performed by
The R Project for Statistical Computing (Windows version
3.1.2) [54]. Because most data did not follow the normal
distribution, nonparametric tests (Kruskal-Wallis tests) were
applied. Since HYS represents an ordinal scale, Chi-square
test was applied for analyses involving HYS. The level of
significance was set at 0.05.
To measure diagnostic accuracy for neurocognitive bat-
teries, Receiver Operating Characteristic (ROC) curve anal-
ysis was obtained [55] to measure sensitivity, specificity,
positive likelihood ratio, negative likelihood ratio, positive
predictive value, negative predictive value, and diagnostic
accuracy.
Because the ideal cut-off is one which selects an immense
amount of disease (high sensitivity) but has very few false
positives (high specificity), we chose the best cut-off point
for balancing the sensitivity and specificity by identifying the
point on the curve closest to the (0, 1) point.
3. Results
One hundred and two patients expressed a coexistent depres-
sion; therefore, they were excluded from further analyses.
Therefore, the data of 370 patients were analyzed subse-
quently. Out of the 370 evaluated subjects, 257 had normal
cognitive profile, 60 had mild neurocognitive disorder, and
53 had major neurocognitive disorder in PD according to
DSM-5 classification. The comparison of the demographic
and clinical characteristics between normal, mild NC, and
major NC groups is presented in Table 1.
Fulfilling our expectations, all the examined dementia
screening scales (MDRS, MoCA, MMSE, and ACE) demon-
strated significant differences between the normal, mild NC,
and major NC groups (Table 1).
Based on ROC analysis, MoCA and ACE had the best
diagnostic accuracy for detecting mild NCD in PD at the
cut-off scores of 23.5 and 83.5 points, respectively (Table 2,
Figure 1). The diagnostic accuracy of these tests was 0.859
(95% confidence interval—CI: 0.818–0.894, MoCA) and
0.820 (95% CI: 0.774–0.859, ACE) meaning 85.9% and 82.0%
of true positive and true negative cases are identified. The
other variables describing the diagnostic accuracy (speci-
ficity, sensitivity, positive and negative predictive values, and
positive and negative likelihood ratios) are presented in
Table 2with their 95%CI values. Area under the curve (AUC)
values are demonstrated in Figure 1.
For detecting major NCD,MoCA andMDRS tests exhib-
ited the highest diagnostic accuracy at the cut-off scores of
20.5 and 132.5 points, respectively (Table 3 and Figure 2).
The diagnostic accuracy of these tests was 0.863 (95% CI:
0.823–0.897,MoCA) and 0.830 (95%CI: 0.785–0.869,MDRS)
meaning 86.3% and 83.0% of true positive and true negative
cases are identified. The other variables describing the diag-
nostic accuracy (specificity, sensitivity, positive and negative
predictive values, and positive and negative likelihood ratios)
are presented in Table 3 with their 95%CI values. AUC values
are demonstrated in Figure 2.
4. Discussion
Screening for NCD in Parkinson’s disease is an important
clinical necessity for establishing diagnosis and initiating
effective and proper treatment. In differentiating between
normal cognition from impaired cognitive abilities an easily
applicable, reproducible, and validated test battery with high
diagnostic accuracy is needed. The aim of our study was to
establish the diagnostic accuracy of widely used screening
tests for detecting mild andmajor neurocognitive disorder in
PD.
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Minor neurocognitive disorder due to PD (DSM-5)
Figure 1: Receiver Operating Characteristic analysis of Adden-
brooke’s Cognitive Examination (ACE), Mattis Dementia Rating
Scale (MDRS), Mini Mental State Examination (MMSE), and
Montreal Cognitive Assessment (MoCA) for detecting mild neu-
rocognitive disorder due to Parkinson’s disease (PD) in accordance
with the Diagnostic and Statistical Manual of Mental Disorders
5th edition criteria. Area under the curve (AUC) values are also
represented with the 95% confidence interval values.
Although some major demographic and PD-related
properties (e.g., education, sex, disease duration, and anti-
Parkinson medication expressed in levodopa equivalent
dosage and severity of depressive symptom measured by
MADRS) were comparable, patients with either minor or
major neurocognitive disorder were older and had higher
age at disease onset andmore severe Parkinsonian symptoms
(MDS-UPDRS and HYS). This is not a surprising factor,
because age and age of disease onset are significant factors for
developing major neurocognitive disorder, and the presence
of cognitive impairment is associated with more severe gait
and postural instability resulting in higher HYS and MDS-
UPDRS Part 3 (Motor Examination) values [56].
To the best of the author’s knowledge, this study is
the first validating the most popular screening tests against
the recently developed mild and major NCD due to PD
established by the DSM-5. Based on our results, MoCA had
better diagnostic accuracy for detecting mild NCD in PD
based on theDSM-5 criteria. Scores<139.5 onMDRS or<83.5
on ACE or <23.5 on MoCA can suggest the presence of mild
NCD in PD (DSM-5). Recent studies revealed similar cut-
off values for MDRS. Villeneuve et al. suggested a normality
cut-off of 138 on the MDRS having the sensitivity of 72%
and specificity of 86% with a correct classification of 80%
for detecting PD-MCI (MDS Task Force criteria) [57]. One
of the limitations of their study was, however, the relatively
low number of PD patients involved (𝑛 = 40). Pirogovsky et
al. published a different study on MDRS having the sample
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ACE AUC: 0.93 (0.90, 0.96)
Major neurocognitive disorder
Figure 2: Receiver Operating Characteristic analysis of Adden-
brooke’s Cognitive Examination (ACE), Mattis Dementia Rating
Scale (MDRS), Mini Mental State Examination (MMSE), and
Montreal Cognitive Assessment (MoCA) for detecting major neu-
rocognitive disorder due to Parkinson’s disease (PD) in accordance
with the Diagnostic and Statistical Manual of Mental Disorders
5th edition criteria. Area under the curve (AUC) values are also
represented with the 95% confidence interval values.
of 30 patients diagnosed with PD-MCI based on Level II
MDS criteria and 68 PD patients with normal cognition.
They suggested that a total score of ≤139 for screening
purposes yielded a better balance between sensitivity (77%)
and specificity (65%) [58].
Previously our team also validated MDRS against the
PDD criteria (MDS Task Force criteria) [14]. In this former
study we suggested the usage of 125 points as a cut-off
score for diagnosing PDD. However, in the present study we
recommended the cut-off of 132.5 points to diagnose major
NCD in PD. This apparent difference might be due to the
larger sample size (370 versus 73), the difference between the
applied diagnostic criteria (major NCD according to DSM-
5 versus PDD established by MDS Task Force), and the
discrepancies between themean educational levels (11.9±4.4
versus 13.0 ± 3.8 years).
Although MMSE is still one of the most frequently
used screening tests, it is generally considered unsuitable
for reliable NCD identification in PD [22]. Despite the
MoCA and MMSE scores which can be converted [59],
MoCA,MDRS, andACE tests appear to be generally superior
for screening NCD in PD [14, 23, 37, 57]. PD subjects
with normal range MMSE but abnormal MoCA scores had
evidence of caudate nucleus dopaminergic denervation and
mild cognitive changes, predominantly in executive function
[60]. PD patients with borderline cognitive impairment have
impairments in their decisional capacity. The MoCA may be
useful to identify the patients at risk of impaired capacity [61].
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The Parkinson Study Group Cognitive/PsychiatricWork-
ing Group recommended MoCA as a minimum cognitive
screening measure in clinical trials of PD where cognitive
performance is not the primary outcome measure [22].
The commonly recommended cut-off screening score for
dementia of 26 on the MoCA is too high for PD patients and
most studies suggest the utilization 23-24 points for cut-off
[62].
However, the application of MoCA in PD-MCI remains
controversial. A recent study [63] demonstrated thatMoCA is
suitable for screening large population for Parkinson’s disease
dementia (PDD, according to MDS Task Force criteria [9]).
On the contrary, other studies showed that when decline
from estimated premorbid levels was considered evidence of
cognitive impairment (Level 2 criteria for PD-MCI), both
MoCAandMMSEhad poor diagnostic accuracy for PD-MCI
(65.3%) [60]. At the lowest cut-off levels that provided at least
80% sensitivity, specificity was low (44%) for the Montreal
Cognitive Assessment [23]. Therefore the authors concluded
that MoCA may be able to preferentially detect executive
dysfunction compared to the MMSE, but the MoCA has
limited diagnostic accuracy for PD-MCI and should not
solely be used to substantiate this diagnosis.
The MoCA may be more sensitive than the MMSE in
detecting early baseline and longitudinal cognitive impair-
ment in PD. Based on the analysis of 95 patients, a MoCA
score of ≤26 provided a sensitivity of 93.1% for the diagnosis
of PD-MCI [64]. In the longitudinal cohort, baseline MoCA
was useful in predicting cognitive decline over 2 years [64].
A baseline MoCA ≤26 was highly predictive of progressive
cognitive decline (HR 3.47, 95% CI: 2.38–5.07; 𝑝 < 0.01) over
2 years. This finding was also confirmed by another study
[65]. The longitudinal data from 155 patients with PD over
18 months showed significant reductions in MoCA scores,
but not in MMSE scores, with 21.3% of patients moving from
normal cognition to MCI and 4.5% moving from MCI to
dementia.
5. Conclusions
DSM-5 criteria for diagnosing mild and major NCD in
PD are clinically feasible. Although most popular screening
tests including MoCA, MDRS, and ACE are proven useful
for screening patients, in the risk population the accurate
diagnosis should be based on appropriate neuropsychological
evaluation.
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